SCHEMBL1663793

SCHEMBL1663793

CC(=O)c1ccc(-c2n[nH]c3ccc(N)cc23)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K4 P45985 12/20 0.59
MAPK1 P28482 5/20 0.59
MAPK6 Q16659 5/20 0.59
MAPKAPK3 Q16644 4/20 0.59
MAPKAPK2 P49137 2/20 0.59
MAPKAPK5 Q8IW41 2/20 0.59
AXL P30530 1/20 0.52
PRKAB2 O43741 1/20 0.48
PRKAG1 P54619 1/20 0.48
PRKAA2 P54646 1/20 0.48
PRKAA1 Q13131 1/20 0.48
PRKAG3 Q9UGI9 1/20 0.48
PRKAG2 Q9UGJ0 1/20 0.48
PRKAB1 Q9Y478 1/20 0.48
FGFR1 P11362 1/20 0.46
FGFR2 P21802 1/20 0.46
JAK2 O60674 1/20 0.45
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45
HTR2B P41595 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1663211 0.83 AXL (0.60) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2
SCHEMBL5377211 0.80 MAP2K4 (0.57) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2
SCHEMBL4006856 0.77 AXL (0.55) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2
SCHEMBL2469031 0.77 AXL (0.55) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2
SCHEMBL12193658 0.77 MKNK1 (0.61) MAPK1AXLFGFR1FGFR2JAK2
SCHEMBL31423230 0.77 DCLK1 (0.65) MAP2K4AXLJAK2HTR2AHTR2C
SCHEMBL4008208 0.77 DCLK1 (0.65) MAP2K4AXLJAK2HTR2AHTR2C
SCHEMBL4009086 0.77 AXL (0.55) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2
Hydrochloric Acid SCHEMBL27750634 0.76 AXL (0.54) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2
Hydrochloric Acid SCHEMBL5390659 0.75 AXL (0.53) MAP2K4MAPK1MAPK6MAPKAPK3MAPKAPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2014-08-28 US disclosed
EP-2642994-A2 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS Ligand Pharmaceuticals Incorporated (US) 2013-10-02 EP disclosed
EP-2488486-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES Ligand Pharmaceuticals Inc. (US) 2012-08-22 EP disclosed
WO-2012068406-A2 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS LIGAND PHARMACEUTICALS INCORPORATED (US) 2012-05-24 WO disclosed
WO-2011046954-A1 HEMATOPOIETIC GROWTH FACTOR MIMETIC SMALL MOLECULE COMPOUNDS AND THEIR USES LIGAND PHARMACEUTICALS INC. (US) 2011-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243324-A1 USE OF HEMATOPOIETIC GROWTH FACTOR MIMETICS HGF, EPOR, MPL MAP2K4 4039/4885MAPK1 4003/4885MAPK6 2466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.